# How an assay separates intact IGF-1 LR3 from its breakdown products

- Article ID: research-391
- Product: TIRZ / IGF-1 LR3 (tirz-igf-1-lr3-712, tirz-igf-1-lr3-713)
- Canonical page: https://heritagebiolabs.com/research-library/articles/391-how-an-assay-separates-intact-igf-1-lr3-from-its-breakdown-products
- Product collection: https://heritagebiolabs.com/research-library/products/tirz-igf-1-lr3
- Product page: https://heritagebiolabs.com/product/tirz-igf-1-lr3-712
- Product page: https://heritagebiolabs.com/product/tirz-igf-1-lr3-713
- Reading focus: Methods & identity (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2021, 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short chains of amino acids linked by peptide bonds. Their sequences help determine which fragments appear when the bonds are cut. Tirzepatide is a peptide that activates GIP and GLP-1 receptors, while IGF-1 LR3 is an engineered growth-factor protein. Older research developed a way to distinguish the intact growth-factor analog from related molecules and some of its breakdown products. [1, 2]

The team used an antibody to enrich related growth-factor molecules from a sample. It then separated the molecules and examined their mass. The study tested the method in human serum to which the researchers had added known materials in the laboratory. That approach shows how the test behaves in a human sample. It does not involve administering the material to human volunteers. [1]

In a separate rat experiment, the researchers could detect intact IGF-1 LR3 for a shorter period than two other growth-factor analogs they studied. They also observed shortened versions of LR3. The time that a laboratory test can detect a molecule depends on the sample, the method and what happens to the molecule in that model. Detection time alone does not establish how long a biological effect lasts. [1]

The test was designed to identify particular IGF molecules. It did not examine tirzepatide or measure how the two components in this entry would affect each other’s exposure. If investigators studied the pair, a method would need to distinguish each ingredient and specify which molecules were counted in the analysis. Evidence that a test can recognize one component is a starting point for measurement, separate from evidence about the pair’s effects. [1, 2]

## Sources

1. Cynthia Mongongu et al. Detection of LongR3-IGF-I, Des(1-3)-IGF-I, and R3-IGF-I using immunopurification and high resolution mass spectrometry for antidoping purposes. Drug Testing and Analysis (publication 2021-02-22). <https://pubmed.ncbi.nlm.nih.gov/33587816/>
2. U.S. Food and Drug Administration. MOUNJARO (tirzepatide) injection, prescribing information. Drugs@FDA (publication 2026-08). <https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s044s045lbl.pdf>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 079 - TIRZ IGF-1 LR3 and Trevogrumab.docx; article 391; content SHA-256 86a7d65f1539e04d2cd0898e36a2017124047d342bcdc225eaa86bea05c9bd28.
